LY 2780301

Drug Profile

LY 2780301

Alternative Names: LY S6KAKT1; LY-2780301

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Institut Paoli-Calmettes; Institute Gustave-Roussy
  • Class Antineoplastics
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • No development reported Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, Late-stage disease, Metastatic disease) in France (PO)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top